Cash/Burn From Filing For Period: 

Q3 '19

XLRN

Acceleron Pharma

Acceleron is a Cambridge, Massachusetts-based biopharmaceutical company dedicated to the discovery and development of innovative, life-changing medicines for patients with serious and rare diseases.

Cash

$426.1M

Burn Rate

$45.4M

Pipeline Information

Click drug data to see upcoming trial info and prior data

Drug | Disease

Stage | Exp Date

Prior Data

Luspatercept (Reblozyl)

Beta-Thalassemia

Approved

1Q 2020

Luspatercept (Reblozyl)

Myelodysplastic syndromes (MDS) cancer

PDUFA

4/4/2020

Luspatercept (Reblozyl)

Myelofibrosis

Phase 3

ACE-083

Charcot-Marie-Tooth disease (CMT)

Phase 2

1Q 2020

Sotatercept

Pulmonary arterial hypertension (PAH)

Phase 2

1Q 2020

Recent Posts

See What The Community Is Saying - Click To See Full Post

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

PROUDLY CREATED WITH WIX.COM

  • Twitter Social Icon
  • LinkedIn Social Icon